The Pharma SIP invest in a sector which is usually less volatile than many cyclical industries, particularly in bear markets. It is because pharmaceutical companies deal in crucial medicines where demand remains relatively stable even during economic slowdowns. However the sector is not completely immune to market corrections and can still decline during major market downturns. In India the Pharma industry benefits from strong export demand, supplying generic medicines to more than 200 nations, including Africa for essential treatments. Historically, healthcare mutual funds have delivered moderate long-term returns of around 10%-14%, though performance can vary across market cycles as compared to other sectors.
What Is a Pharma Mutual Fund?
A Pharma fund refers to the sectoral mutual fund which invests mainly in Pharmaceutical and healthcare companies. According to the SEBI rules, Pharma invests at least 80% of its assets in stocks of companies from this particular sector. For instance, the Aditya Birla Sun Life Pharma and healthcare fund specially invests in Pharma and healthcare related companies to generate long term returns.
Pharma companies often perform gradually even during an economic slowdown, as the demand for medicines remains constant. It makes Pharma funds a potential option for long term growth and relatively stable investment.
Start Your SIP TodayLet your money work for you with the best SIP plans.
Why Pharma Funds Don't Fall Much Even When the Market Crashes?
Pharma funds are often considered comparatively defensive in a market slowdown. However this stability comes from several key factors:
- Inelastic Demand: : Medicines are a necessity in all economic conditions thus demand for Pharma products remains steady even during recessions or market crashes.
- Strong Export Market: India is a major global supplier of affordable generic medicines, particularly to African countries for diseases like malaria, HIV, and infections.
- Generic Medicine Strength: India Pharma companies earn prominently from low cost generics that have steady global demand and are less linked to economic cycles.
- Defensive Sector Behaviour: During market volatility investors often shift money into defensive sectors such as Pharma that help reduce sharp downside in price.
- Structural Backstop: India's pharmaceutical sector enjoys consistent policy support. PLI schemes for bulk drugs and medical devices, Jan Aushadhi Kendras and the government's push to reduce API import dependence from China.
- Historical Performance Insight: For longer periods, Pharma sector funds in India have typically delivered moderate returns (~ 10%-14% CAGR range over 5 to 10 years) with comparatively lower drawdowns as compared to broader equity markets during corrections.
Which Type of Investor Should Actually Put Money in Pharma Funds?
Sectoral funds can provide strong returns when their sector performs well. But they can also face sharp declines during weak market phases. Since Pharma funds invest mainly in one industry, their performance depends heavily on the Pharma sector itself. Below is a balanced view of who may benefit from investing in top Pharma mutual funds and who should be more cautious.
The Satellite Allocator
Having a core portfolio of diversified/flexi cap funds/ large cap mutual funds, and now wants to add 10-15% of the portfolio in a high conviction sector for additional alpha.
The Long-Horizon Investor
Those willing to ride 2-3 years under performance cycles within a structural growth story. Those who have the conviction to stay invested through USFDA headwinds or pricing pressure phases.
The Macro-Aware HNI
Understand the structural tailwinds including global generics dominance, ageing demographics, export growth,
The First-Time Investor
If you are just starting your mutual fund journey, then avoid making sectoral funds your first investment. It is usually better to build a strong base with diversified equity mutual funds first as sector based investing can be riskier and more volatile.
The Short-Term Trader
Pharma cycles are long, and the sector can underperform for 2-3 consecutive years. Investors with a 1-2 year horizon take a maximal timing risk with minimal probability of reward.
The Risk Averse Retiree
Even though Pharma funds are comparatively defensive, it still carry sector specific risk. So investors who prefer stable capital and lower volatility should avoid heavy exposure to a single sector.
Monthly SIP or One-Time Lumpsum: Which is Better for Pharma?
Choosing between SIP and lumsum investing in sectoral funds is not always an easy option. The better option mainly depends on the sector's market cycle, followed by investment timing. Below is a simple breakdown to know both approached more suitable.
| SIP - The Case For | Lumpsum - The Case For |
|---|---|
| Averages cost across pharma's inherent volatility cycles | Superior when the sector is at a cycle low or coming out of a multi-year downturn |
| Removes the dangerous temptation to time the sector | Captures the full upside of a sector re-rating event faster than SIP |
| Builds position gradually — lowers regret risk if sector corrects post-investment | Appropriate when Nifty Pharma P/E is at a significant discount to the 5-year average |
| Mathematically superior in volatile, range-bound phases | Works for macro-driven entry signals (e.g., USFDA resolution cycle, INR depreciation) |
| ₹5,000 SIP over 5 years in SBI Healthcare = ~₹4.75 lakhs corpus (at ~17% XIRR) | Requires conviction, timing discipline, and a clear exit framework |
| Best suited for investors with no specific view on sector valuation | — |
Top Performing Pharma Mutual Funds in India
Below is the top selected list of leading best pharma mutual funds and healthcare mutual funds in India. This is evaluated with the help of vital factors like long term returns, consistency, fund manager performance, AUM size and overall risk adjusted performance. The following are the data of the best Pharma mutual fund on the basis of publicly available details as of early 2026.
| Fund Name | AUM (₹ Cr) | 3Y Return | 5Y Return | Min SIP | Expert View |
|---|---|---|---|---|---|
| SBI Healthcare Opportunities Fund SBI Mutual Fund · Inception: Jul 1999 |
₹3,849 | 28.00% | 23.50% | ₹500 | Top Pick |
| ICICI Pru Pharma Healthcare & Diagnostics ICICI Prudential MF |
₹1,229 | 28.00% | ~17% | ₹100 | Strong |
| UTI Healthcare Fund UTI Mutual Fund · Inception: Aug 2005 |
₹1,099 | 26.30% | 21.70% | ₹500 | Strong |
| DSP Healthcare Fund DSP Mutual Fund · Inception: Nov 2018 |
₹858 | 24.00% | 14%+ | ₹100 | Watch |
| WhiteOak Capital Pharma & Healthcare Fund WhiteOak MF · Inception: Feb 2024 |
₹556 | — | — | ₹500 | Monitor (New) |
| Nippon India Pharma Fund Nippon India MF |
~₹900+ | ~23% | ~15% | ₹100 | Consistent |
Pro Tip: With the help of our SIP calculator, understand how continuous investing and compounding can help you build wealth.
Why Pharma Is the Smartest Bet If You're Investing for 10+ Years?
The vital factor to invest in a 10-year Pharma SIP is not just compounding returns. However, the strong structural growth is behind the sector. Demographic changes, rising healthcare requirements and the global role of India in pharmaceuticals make long term growth highly likely over the next decade.
This is how the 10 year windows are uniquely powerful for Pharma mutual funds in brief:
- 2026-208
- USFDA approvals accelerating for Indian investors
- API import substitution from China is gathering momentum under PLI schemes.
- The domestic formulations market is expanding into tier2/3 cities.
- 2028-2030
- India's CDMO/CRAMS sector is projected to scale significantly.
- Global Pharma companies are accelerating outsourcing to India.
- The biosimilars opportunity opens a new high-margin revenue stream for top players.
- 2030-2034
- The Indian pharma market is projected to reach $145–175 billion.
- Medical tourism is expected to exceed $13 billion.
- India's ageing population drives chronic disease management spending structurally higher.
Smart Investments, Bigger Returns
Why Pharma is the Future: A Deep Analysis
The following are the five long term trends driving India's Pharma sector:
Global Pharma Strength
India supplies approximately 20% of global generic medicines and exports to more than 200 nations with a growing shift towards higher value drugs.
Biosimilar Opportunity
Secondly, further expiring global drug patents are creating a large biosimilars market with better margins and strong growth potential.
Increasing Global Outsourcing
Pharma firms globally are increasingly outsourcing manufacturing and R&D to India for cost and efficiency advantages.
Robust Domestic Demand
Increasingly lifestyle diseases like diabetes and heart conditions are driving steady long term medicine consumption in India.
AI & Innovation Push
The combination of Pharma expertise and tech talent is supporting advancements in AI-driven drug innovation.
Why Our Platform is Your Safest Bet for Pharma SIPs?
Choosing the accurate Pharma fund is crucial, but having the right guidance and monitoring equally matters. Below is how MySIPonline helps investors make informed decisions:
Research Oriented Selection
Funds are assessed beyond the past returns with the help of consistency, benchmark comparison, and fund manager performance.
Portfolio Focused Approach
Recommendations are made on the basis of your overall portfolio, risk profile and existing sector exposure.
AI- Assisted Monitoring
Our platforms track fund performance, benchmark trends and major changes to offer timely insights.
Experienced Investment Support
The team brings their expertise across mutual funds and other investment segments to assist investors in choosing proper strategies.
Conclusion
Pharma SIP provides a nice balance of relative stability and long term growth potential. This is largely influenced by crucial healthcare demand, strong export leadership, and structural industry trends. The sector is not risk free and may face cyclical under performance, whereas its defensive nature makes it suitable for disciplined, long term investors. For a more than 10 year horizon, Pharma funds can act as a strong satellite allocation within a diversified portfolio. It helps investors navigate volatility while simultaneously participating in the steady expansion of the global economy sector.
FAQ’s -
Is There Any Pharma ETFIn India?
Nippon India is one such ETF that tracks major pharmaceutical companies listed on the Nifty Pharma Index.
Who is the King of Pharma?
Sun Pharmaceutical Industries is considered the king of pharma in India because of its market leadership, global presence, and strong revenue growth across multiple healthcare segments.
What is the Future of Pharma in India?
The future of India's Pharma sector looks quite strong with rising healthcare demand, innovation, exports and government support. This makes it one of the fastest growing industries worldwide over the coming decade.
How Many Types of Pharma Funds are in India?
India mainly has three types of Pharma mutual funds including Pharma sector funds, healthcare funds and Pharma ETFs. These funds invest in biotech, healthcare related field and pharmaceutical related companies.
